Cancer cachexia: A therapeutic approach

Medicinal Research Reviews

Volumn 21, Issue 1, 2001, Pages 83-101

  Argils Sebastiaan H Meijsing, Josep M ^a,b   Pallars Trujillo, Javier ^a   Guirao, Xavier ^b   Lpez Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE FIGUERES   (Spain)

Author keywords

Anorexia; Cachexia; Therapy; Tumor

Indexed keywords

ANABOLIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID; CLENBUTEROL; CORTICOSTEROID; CYPROHEPTADINE; CYTOKINE ANTIBODY; DEXAMETHASONE; DRONABINOL; GAMMA INTERFERON ANTIBODY; GESTAGEN; GROWTH HORMONE; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 6 ANTIBODY; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELATONIN; NANDROLONE DECANOATE; OXYMETHOLONE; PENTOXIFYLLINE; POLYUNSATURATED FATTY ACID; PREDNISOLONE; PROGESTERONE DERIVATIVE; ROLIPRAM; SOMATOMEDIN C; SOMATOSTATIN; THALIDOMIDE; UNINDEXED DRUG;

ADVANCED CANCER; ANOREXIA; CACHEXIA; CANCER; CAUSE OF DEATH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; ENTERIC FEEDING; GLUCOSE INTOLERANCE; HUMAN; LIPID METABOLISM; METABOLIC DISORDER; PROTEIN DEGRADATION; REVIEW; TOTAL PARENTERAL NUTRITION;

CACHEXIA; HUMANS; NEOPLASMS;

EID: 0035173858     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1128(200101)21:1<83::AID-MED4>3.0.CO;2-1     Document Type: Review

References (119)

1. The immediate cause of death in cancer
2. The metabolic basis of cancer cachexia
3. Nutritional assessment and patient outcome during oncological therapy
4. Protein-caloric undernutrition in hospitalized cancer patients
5. Management of cancer cachexia
6. The role of cytokines in muscle wasting: Its relation with cancer cachexia
7. Asthenia
8. Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies
9. Phase III evaluation of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia
10. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer
11. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: A multicentric cooperative study
12. Megestrol acetate stimulates food and water intake in the rat: Effects on regional hypothalamic neuropeptide Y concentrations
13. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells and cancer patients
14. Megestrol acetate in patients with AIDS-related cachexia
15. Body-composition changes in patients who gain weight while receiving megestrol acetate
16. The effects of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients
17. Effect of megestrol acetate on weight loss induced by tumour necrosis factor-α and a cachexia-inducing tumour (MAC-16) in NMRI mice
18. Recent clinical experience with dronabinol
19. Pharmacological agents affecting emesis: A review
20. Marijuana components stimulate peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1-alpha in vitro
21. Antiemetics in patients receiving chemotherapy for cancer: A randomized comparison of delta-9-tetrahydrocannabinoid and prochlorperazine
22. Increased availability of tryptophan in brain as a common pathogenic mechanism for anorexia associated with different diseases
23. Cracking the riddle of cancer anorexia
24. A controlled trial of cyproheptadine in cancer patients with anorexia
25. Preoperative insulin reverses cachexia and decreases mortality in tumor-bearing rats
26. Humoral mediation for cachexia in tumor-bearing rats
27. Body composition changes in rats with experimental cachexia: Improvements with exogenous insulin
28. Effect of insulin on weight loss and tumour growth in a cachexia model
29. Anorexia and cachexia in advanced cancer patients
30. Psychopharmacologic applications to cancer
31. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
32. Cytokine mediators of malnutrition: Clinical implications
33. Cytokines and glucocorticoids in the regulation of the "hepato-skeletal muscle axis" in sepsis
34. Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486
35. Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia
36. Preoperative parenteral feeding in patients with gastrointestinal cancer
37. Total parenteral nutrition and cancer clinical trials
38. Metabolic effects of tumour necrosis factor-α (cachectin) and interleukin-1
39. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon-26-induced cachexia in mice
40. Immunological aspects of the effect of pentoxifylline (Trental)
41. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial
42. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS
43. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
44. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rollipram in a murine model of endotoxic shock
45. Thalidomide selectively inhibits tumor necrosis factor-α production in stimulated human monocytes
46. The influence of thalidomide on the clinical and immunological manifestation of erithema nodosum leprosum
47. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation
48. Thalidomide treatment reduces tumor necrosis factor-α production and enhances weight gain in patients with pulmonary tuberculosis
49. Anti-tumour necrosis factor-α treatment interferes with changes in lipid metabolism in a tumour cachexia model
50. Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model
51. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
52. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice
53. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo
54. Administration of an interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms
55. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia
56. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130)
57. Murine interleukin-12 prevents the development of cancer cachexia in a murine model
58. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice
59. Establishment and characterization of cachexia-inducing and non-inducing clones of murine colon 26 carcinoma
60. Interleukin-6 involvement in mesothelioma pathobiology: Inhibition by interferon-α immunotherapy
61. Interleukin-15: A novel anabolic cytokine for skeletal muscle
62. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats
63. Growth hormone and insulin combine to improve whole-body and skeletal protein kinetics
64. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans
65. Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition
66. Growth hormone and insulin reverse net whole-body and skeletal muscle protein catabolism in cancer patients
67. Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin
68. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection
69. Actions of insulin-like growth factors
70. Hormonal control of muscle growth
71. Growth hormone and the insulin-like factor system in myogenesis
72. Insulin-like growth factor I production is inhibited in human sepsis
73. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia
74. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome
75. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: A study of interactions between tumor necrosis factor-α and the pineal hormone melatonin
76. Is there a role for melatonin in the treatment of neoplastic cachexia?
77. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state
78. Growth hormone, insulin, and somatostatin therapy of cancer cachexia
79. Interferons and tumor necrosis factor have similar catabolic effects on 3T3L1 cells
80. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection
81. 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway
82. 2-adrenergic agonists on muscle waste associated with tumour growth
83. Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol
84. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer
85. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice
86. Mechanism of lipid mobilization associated with cancer cachexia: Interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein
87. Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover
88. Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumour growth
89. The effect of polYUnsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer
90. Improved protein kinetics and albumin synthesis by branched-chain amino acid-enriched total parenteral nutriton in cancer cachexia
91. Branched-chain amino acids as the protein component of parenteral nutrition in cancer cachexia
92. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients
93. Brain tryptophan and the neoplastic anorexia-cachexia syndrome
94. The early cancer anorexia paradigm: Changes in plasma free tryptophan and feeding indexes
95. Dietary effects on brain serotonin synthesis: Relationship to appetite regulation
96. Glutamine and cancer
97. Amino acid metabolism in tumour-bearing mice
98. Tumor regulation of hepatic glutamine metabolism
99. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study
100. Glutamine facilitates chemotherapy while reducing toxicity
101. From laboratory to bedside: New strategies in the treatment of malnutrition in cancer patients
102. Role of cysteine and glutathione in HIV infection and cancer cachexia: Therapeutic intervention with N-acetylcysteine
103. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer
104. Abnormal glutathione and sulfate levels after interleukin-6 treatment in tumor-induced cachexia
105. Reversal of immunosuppression induced by a protein-free diet: Comparison of nucleotides, fish oil, and arginine
106. Use of hydrazine sulphate in terminal and pre-terminal cancer patients: Results of investigation of new drug (IND) study in 84 evaluable patients
107. Hydrazine sulphate influence of nutritional status and survival in non-small ceil lung cancer
108. 14C-lysine metabolism in lung cancer patients
109. 9-Deoxy-delta 9, delta 12-13, 14 dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human placenta
110. Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: A comparison between SENCAR and NMRI mice
111. Cancer growth, response to treatment and survival time in mice: Beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen
112. Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated diarrhoea
113. Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats
114. The effects of cyclooxigenase inhibitors on tumor-induced anorexia in rats
115. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine
116. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors
117. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma
118. 5′deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice
119. Journey from cachexia to obesity by TNF